Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib

Pediatr Hematol Oncol. 2011 Nov;28(8):669-75. doi: 10.3109/08880018.2011.615048.

Abstract

Chronic myelogenous leukemia (CML) constitutes less than 5% of childhood leukemias. The authors describe a rare case of a 14-year-old boy who presented with CML in blast crisis. Unique to this patient was the evidence of both breakpoint cluster region-c-abl oncogene 1 (BCR-ABL1) fusions as well as an additional unbalanced t(1;19) translocation. This combination has not previously been reported in the same patient. Initial treatment with dasatinib achieved a complete cytogenetic response within 2 months of therapy. This case highlights the heterogeneous presentation of CML in children and rationale for use of dasatinib as a first-line agent for patients with blast crisis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Blast Crisis / diagnosis
  • Blast Crisis / genetics*
  • Blast Crisis / therapy
  • Bone Marrow Transplantation
  • Chromosomes, Human, Pair 1 / genetics*
  • Chromosomes, Human, Pair 19 / genetics*
  • Dasatinib
  • Fatal Outcome
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Philadelphia Chromosome*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*

Substances

  • Pyrimidines
  • Thiazoles
  • Dasatinib